Quoin Pharmaceuticals (NASDAQ:QNRX) CFO Sally Bridget Lawlor Purchases 10,244 Shares

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) CFO Sally Bridget Lawlor purchased 10,244 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The stock was bought at an average cost of $4.88 per share, with a total value of $49,990.72. Following the completion of the transaction, the chief financial officer directly owned 10,684 shares of the company’s stock, valued at $52,137.92. This represents a 2,328.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX opened at $6.51 on Wednesday. The company has a market capitalization of $13.09 million, a PE ratio of -0.26 and a beta of 1.50. The company’s 50 day moving average price is $4.77 and its 200 day moving average price is $5.89. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 52 week low of $3.25 and a 52 week high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). On average, equities analysts forecast that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

QNRX has been the topic of several research analyst reports. ThinkEquity started coverage on Quoin Pharmaceuticals in a research report on Monday, June 15th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QNRX. Simplify Asset Management Inc. acquired a new position in Quoin Pharmaceuticals in the 4th quarter valued at approximately $252,000. ADAR1 Capital Management LLC acquired a new stake in shares of Quoin Pharmaceuticals during the 4th quarter worth approximately $840,000. Boothbay Fund Management LLC bought a new stake in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $863,000. Millennium Management LLC bought a new stake in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at $935,000. Institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.